Disparity Expression Of Erythropoietin And Its Receptor In Radical Prostatectomy Patients Undergoing Neoadjuvant Hormone Therapy

Disparity expression of erythropoietin and its receptor in radical prostatectomy patients undergoing neoadjuvant hormone therapyBackground:Prostate carcinoma (PCa) is one of the most common malignances among the urological neoplasms and the incidence of PCa is getting higher in China today with the aging and the diet habit changing. Radical prostatectomy is an curative form of treatment of organ confined prostatic carcinoma. However, the lack of reliable and accurate clinical staging judgment standardization frequently leads to incomplete excision of tumor,with the consequences of early local recurrence or distant metastasis. Randomized trials evaluating the use of neoadjuvant hormonal therapy (NHT) have consistently shown significant decreases in prostate volume and in PSA levels, and cause a significant reduction in the incidence of positive surgical margins, however the incidence of seminal vesicle invasion and metastases to the pelvic lymph nodes does not differ compared to controls. Hypoxia is a common phenomenon in solid tumors, resulting from inadequate blood supply with impaired vascular function. A research of Copenhagen rats injected Dunning R-3327 AT-1 rat prostate tumor cells into the prostate confirmed that there is a hypoxia phenomenon in prostate after castration. Hypoxia stress has not always been considered to be adverse to the survival and growth of tumors.Purpose:To investigate disparity expression of erythropoietin and its receptor in radical prostatectomy patients after neoadjuvant hormone therapy.Methods:The 10 radical prostatectomy specimens after NHT as well as needle biopsy specimens before NHT were examined erythropoietin and its receptor distribution by using immunohi stochemi stryResults:over-expression of EPOR was mainly shown in all biosy and prostatectomy samples. Over-expression of EPO was observed in 50%(5/10)of the biosy samples, while various degrees of EPO over expression were observed in all the samples after NHT. The therapeutic effects of 50 cases with NHT were assessed as good (20 cases) or poor (30 cases). Statistical analysis demonstrated that higher EPO staining score in prostatectomy samples than in biosy samples (P<0.05). But the expressions of EPOR are not different in biosy and prostatectomy samples (P<0.05). The Gleason score is higher in prostatectomy samples than in biosy samples (P<0.05). There are 80% patients whose clinical stage of postoperation is higher preoperation. The expressions of EPO are not corelative to Gleason in the patients with NHT. The different Gleason score between the biosy and prostatectomy samples is not correlative to the different expressions of EPO between biosy and prostatectomy samples (P>0.05).Conclusion:HIF-la is expected to serve as a useful assistant marker for detection of the viability of PAs after NHT and also for predicting their clinical behavior. In addition, the expression may contribute to histological discriminate the carcinoma cells.